See the associated article on page [717][1]. One of the most discussed controversies in the management of patients with well-differentiated thyroid cancer (DTC) is selection of the activity for 131I therapy. One of the problems is that prima facie evidence (i.e., first-look evidence) may lead to
No takes yet. Share an insight, caveat, or question.
Douglas Van Nostrand (2017) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: